Overview

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Novartis
Treatments:
asciminib